Now Playing
|Videos|June 4, 2021
Pathophysiology and Symptoms of Ulcerative Colitis
Andres Yarur, MD, of the Medical College of Wisconsin, comments on the chronic, progressive nature of ulcerative colitis and highlights special considerations for classifying patients based on disease severity.
Advertisement
Episodes in this series
Advertisement
Related to this article
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Trending on HCPLive
1
Second-Line Therapy in Fibrillary GN: Secondary Causes and Rituximab Data
2
Ixekizumab, Tirzepatide Broaden Biomarker Effects in Psoriasis, Obesity
3
Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD
4
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
5